# OnCo record paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023" ;
  schema:name "Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms"@en ;
  schema:description "In 232 Swedish early triple-negative cancers, half were PD-L1-positive by the atezolizumab test (SP142 IC 1%) but only 27% by the pembrolizumab threshold (22C3 CPS 10), and the two tests picked partly different patients."@en ;
  schema:url <https://onco.cc/key-papers/paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1186/s13058-023-01724-2>, <https://pubmed.ncbi.nlm.nih.gov/37817263/> ;
  schema:sameAs <https://doi.org/10.1186/s13058-023-01724-2> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Sigurjonsdottir G, De Marchi T, Ehinger A, et al." ;
  onco:related <https://onco.cc/biomarkers/pd-l1-ic-score/>, <https://onco.cc/biomarkers/pd-l1-cps/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/ventana-pd-l1-sp142/>, <https://onco.cc/drugs/dako-pd-l1-22c3-pharmdx/> ;
  onco:institutions <https://onco.cc/institutions/lund-skane/> ;
  onco:terms <https://onco.cc/terms/cps/>, <https://onco.cc/terms/tils/>, <https://onco.cc/terms/ihc/> ;
  onco:journals <https://onco.cc/journals/breast-cancer-research/> .